Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00567086 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Safety, Tolerance and Efficacy of Tezampanel in Patients With Acute Migraine
A Phase 2 study, sponsored by TorreyPines Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 306
- Enrollment target
NCT00567086 is a Phase 2 study that has completed, run by TorreyPines Therapeutics. The registered enrollment target is 306 participants.
The verdict
NCT00567086, a Phase 2 study, has completed, sponsored by TorreyPines Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 306 participants
- Enrollment target
Study Summary
To evaluate the effects of a single sc administration of TEZAMPANEL at one of three different dosage levels compared to placebo, employing traditional measures of efficacy and safety in the treatment of a single episode of acute migraine.
Interventions
- DRUG TEZAMPANEL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 306 participants |
| Start Date | 2006-10 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00567086
The ClinicalTrials.gov registry entry for NCT00567086 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 306 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TorreyPines Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TEZAMPANEL is the first listed.
NCT00567086 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00567086 about?
NCT00567086 is a clinical study titled "Study to Assess the Safety, Tolerance and Efficacy of Tezampanel in Patients With Acute Migraine". To evaluate the effects of a single sc administration of TEZAMPANEL at one of three different dosage levels compared to placebo, employing traditional measures of efficacy and safety in the treatment of a single episode of acute migraine.
What is the current status of trial NCT00567086?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 306 participants. The study started on 2006-10. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00567086?
The interventions under investigation include: TEZAMPANEL (DRUG).
Who is sponsoring clinical trial NCT00567086?
This trial is sponsored by TorreyPines Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.